MetaCap

CytoMed Therapeutics (GDTC) vs Optimi Health (OPTH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

CytoMed Therapeutics is the larger company by market cap ($9.0 million vs $8.6 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GDTC-42.80%OPTH-75.16%
+4%-38%-79%
May 20, 20261 yearNov 20, 2026
GDTC-33.19%OPTH-74.19%
+19%-30%-79%
May 18, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GDTC versus OPTH key metrics
MetricGDTCOPTH
Share price$0.755$1.51
Market cap$9.01M$8.65M
1-day change-2.33%-13.71%
YTD return-43.45%—
1-year return-59.84%—
EPS (TTM)$-0.23$-1.56
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$252.26K—
Revenue growth (YoY)+395.88%—
Net income (latest FY)$-3.10M—
Net margin-1227.07%—
52-week high$2.12$6.40
52-week low$0.68$1.51
Distance from 52-week high-64.39%-76.41%
Analyst consensusnone—
Avg. price target upside+450.99%—
Average volume15.69K43.55K
Shares outstanding11.93M5.73M
Employees42—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About CytoMed Therapeutics

GDTC stock →

CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.

Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees

About Optimi Health

OPTH stock →

Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations

GDTC vs OPTH FAQ

Which is bigger, CytoMed Therapeutics or Optimi Health?

CytoMed Therapeutics (GDTC) is larger, with a market capitalization of $9.01M compared with $8.65M for Optimi Health (OPTH).

Are CytoMed Therapeutics and Optimi Health in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons